Functional study of the 830C>G polymorphism of the human carboxylesterase 2 gene

Purpose Carboxylesterase 2 (CES2) is involved in the activation of the anticancer drug irinotecan to its active metabolite SN-38. We previously identified a single nucleotide polymorphism (SNP), with an allele frequency around 10%, as possibly involved in enzyme expression (Clin Pharmacol Ther 76:528-535, 2004), which could explain the large individual variation in SN-38 disposition. Methods The 830C > G SNP, located in the 5' untranslated region of the gene, was analysed in various DNA samples extracted from: (1) the National Cancer Institute NCI-60 panel of human tumour cell lines; (2) a collection of 104 samples of normal tissue from colorectal cancer patients; (3) blood samples from a population of 95 normal subjects; (4) a collection of 285 human livers. CES2 genotypes were tentatively related to irinotecan cytotoxicity and CES2 expression in the NCI-60 panel; to response to treatment and event-free survival in colorectal cancer patients; and to CES2 expression and catalytic activity in subsets of the human liver collection. Reults No significant relationship was found in the NCI-60 panel between CES2 830C > G genotype and irinotecan cytotoxicity or CES2 expression. No significant relationship was found between CES2 830C > G genotype and the toxicity and therapeutic efficacy (tumour response, event-free survival) of irinotecan in colorectal cancer patients. There was no significant relationship between CES2 830C > G genotype and CES2 expression and catalytic activity determined in a subset of genotype-selected liver samples. Conclusion The 830C > G SNP of CES2 is unlikely to have significant functional consequences on CES2 expression, activity or function.